EMA/336633/2023

European Medicines Agency decision

P/0306/2023

of 11 August 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral for dirloctocogene samoparvovec, (EMEA-003290-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0306/2023

of 11 August 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral for dirloctocogene samoparvovec, (EMEA-003290-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Spark Therapeutics Ireland Limited on 1 August 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for dirloctocogene samoparvovec, solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for dirloctocogene samoparvovec, solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Spark Therapeutics Ireland Limited, 6th Floor 2 Grand Canal Quay Dublin 2 Co., D02 A342 – Dublin, Ireland.

EMA/PDCO/152214/2023
Amsterdam, 23 June 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-003290-PIP01-22

Scope of the application

Active substance(s):

Dirloctocogene samoparvovec

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of moderate or severe haemophilia A without Factor VIII inhibitors

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Spark Therapeutics Ireland Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Spark Therapeutics Ireland Limited submitted for agreement to the European Medicines Agency on 1 August 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 12 September 2022.

Supplementary information was provided by the applicant on 17 March 2023. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of haemophilia A

2.1.1. Indication(s) targeted by the PIP

Dirloctocogene samoparvovec is indicated for treatment of patients with moderate or severe haemophilia A without factor VIII (FVIII) inhibitors

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	**Study 1 (STUYY-XXXX)** Exploratory toxicity and efficacy study testing three different doses of AAV-Spark100-hFVIII vector (SPK-8005) administered intravenously in male C57Bl/6 mice at ages spanning neonatal development to adulthood. **Study 2 (STUYY-XXXX(+1))** Juvenile toxicity study in male C57Bl/6 mice will be performed to assess durability and safety of the hFVIII transgene.
Clinical studies	**Study 3 (SPK-8011-30X)** Open-label, multicenter, single-arm study with intraparticipant control to evaluate the safety and efficacy of Dirloctocogene samoparvovec SPK-8011 in paediatric patients from 12 years to less than 18 years of age with moderate or severe haemophilia A without coagulation factor VIII (FVIII) inhibitors. **Study 4 (SPK-8011-30Y)** Open-label, multicenter, single-arm study with intraparticipant control to to evaluate the safety and efficacy of Dirloctocogene samoparvovecin paediatric patients from 4 years to less than 12 years

	of age with moderate or severe haemophilia A without coagulation FVII inhibitors. **Study 5 (SPK-8011-30Z)** Open-label, multicenter, single-arm study with intraparticipant control to evaluate the safety and efficacy of Dirloctocogene samoparvovec in paediatric patients from birth to less than 4 years of age with moderate or severe haemophilia A without coagulation FVII inhibitors.
Modelling and simulation studies	Not applicable
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2043
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.